Significance of Loss of Heterozygosity in Predicting Axillary Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast

被引:2
作者
Lin, Xiaoqi [1 ]
Zhu, Bing [1 ]
Finkelstein, Sydney D. [2 ]
Saad, Reda S. [4 ]
Snitchler, Andrea [3 ]
Silverman, Jan F. [3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, NW Mem Hosp, Dept Pathol, Chicago, IL 60611 USA
[2] RedPath Integrated Pathol Inc, Pittsburgh, PA USA
[3] Allegheny Gen Hosp, Dept Pathol, Pittsburgh, PA 15212 USA
[4] Univ Toronto, Dept Pathol, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
来源
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2012年 / 20卷 / 02期
关键词
invasive ductal carcinoma; axillary lymph node; loss of heterozygosity; COMPARATIVE GENOMIC HYBRIDIZATION; CANCER CELLS; ALLELIC LOSS; IN-SITU; PROGNOSTIC-SIGNIFICANCE; ESTROGEN-RECEPTOR; EXPRESSION; PROGRESSION; LESIONS; GENE;
D O I
10.1097/PAI.0b013e31822afce2
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Invasive ductal carcinoma (IDC) of breast metastatic to axillary lymph node (ALN) is a critical factor in determining stage and is a strong predictor of disease prognosis and survival. We studied ALN metastasis using a combined histopathologic/molecular approach to gain insights into the pathobiology implications. Fourteen patients with IDC with positive ALN and 19 with negative ALN were retrieved. Analysis of 17 polymorphic microsatellite repeat markers targeting 1p34-36, 3p24-26, 5q23, 9p21, 10q23, 17p13, 17q12, 17q21, 21q22, and 22q13 was carried out in DNA isolated from primary tumors and metastatic tumors. ALN metastasis correlated with fractional mutation rate of primary and ALN metastatic tumors, primary tumor size, and nuclear grade, and did not correlate with expression of estrogen receptor, progesterone receptor, and Her2/neu. Loss of heterozygosity (LOH) detected at 1p34-36, 3p24-26, 9p21, 10q23, 17p13, 17q12, 21q22, and 22q13 may play an important role in the development and aggressiveness of IDC, and LOHs at 1p34-36, 17p13, and 22q13 may play an important role in metastasis. None of the LOHs were shared by all the tumors, suggesting that IDC develops through various pathways that have unique and personalized patterns of mutational changes, although they share similar morphology. Detection of LOH in IDC is not only useful in studying oncogenesis, but also predicting aggressiveness and ALN metastasis.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 54 条
[1]   A candidate metastasis-associated DNA marker for ductal mammary carcinoma [J].
Achary, PMR ;
Zhao, H ;
Fan, ZH ;
Gogineni, S ;
Pulijaal, VR ;
Herbst, L ;
Mahadevia, PS ;
Jones, JG ;
Klinger, HP ;
Vikram, B .
BREAST CANCER RESEARCH, 2003, 5 (02) :R52-R58
[2]   Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer [J].
Aubele, MM ;
Cummings, MC ;
Mattis, AE ;
Zitzelsberger, HF ;
Walch, AK ;
Kremer, M ;
Höfler, H ;
Werner, M .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (01) :14-19
[3]   C-myc amplifications in primary breast carcinomas and their local recurrences [J].
Aulmann, S ;
Adler, N ;
Rom, J ;
Helmchen, B ;
Schirmacher, P ;
Sinn, HP .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (04) :424-428
[4]   C-myc oncogene amplification in ductal carcinoma in situ of the breast [J].
Aulmann, S ;
Bentz, M ;
Sinn, HP .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (01) :25-31
[5]   PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer [J].
Bandyopadhyay, S ;
Pai, SK ;
Hirota, S ;
Hosobe, S ;
Tsukada, T ;
Miura, K ;
Takano, Y ;
Saito, K ;
Commes, T ;
Piquemal, D ;
Watabe, M ;
Gross, S ;
Wang, Y ;
Huggenvik, J ;
Watabe, K .
CANCER RESEARCH, 2004, 64 (21) :7655-7660
[6]  
BONSING BA, 1993, CANCER RES, V53, P3804
[7]  
Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO
[8]  
2-2
[9]  
Castells A, 2000, CANCER RES, V60, P2836
[10]   HETEROGENEITY FOR ALLELIC LOSS IN HUMAN BREAST-CANCER [J].
CHEN, LC ;
KURISU, W ;
LJUNG, BM ;
GOLDMAN, ES ;
MOORE, D ;
SMITH, HS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (07) :506-510